Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical outcomes of adjuvant chemotherapy for pancreatic cancer: A collaborative study from the JASPAC 01 trial.

ABSTRACT:

Background

Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. However, predictive values of immunohistochemical hENT1 expression may differ according to the antibodies, 10D7G2 and SP120.

Aim

We aimed to investigate the concordance of immunohistochemical hENT1 expression between the two antibodies and prognosis.

Methods

The subjects of this study were totally 332 whose formalin-fixed paraffin-embedded specimens and/or unstained sections were obtained. The individual H-scores and four classifications according to the staining intensity were applied for the evaluation of hENT1 expression by 10D7G2 and SP120, respectively.

Results

The highest concordance rate (79.8%) was obtained

SUBMITTER: Okamura Y 

PROVIDER: S-EPMC9124504 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature